Review Article

The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-Cell Lymphoma

Table 2

Phase III trials of HDT/ASCT in unfavorable NHL patients.

Author Year Histological classificationDLCL (%)Immunological phenotype (%) aaIPI ≥ 2 (%)Disease status HDT/ASCTTherapyShorten induction yes/noPFS/EFS (%) OS (%)

Gianni [17] 199758
40
W.F.88
91
N.R.74
94
CR, CRu, PR, SD, MR, PDMACOP-B2 versus HDS# + mito-L-PAM2/ASCT No7y: 49
7y : 76
<0.0017y: 55
7y : 81
0.09

Santini [18] 199861
63
W.F.72
77
B: 75
B: 83
59
54
CR, CRu, PR, SD, MR, PDVACOP-B1 versus VACOP-B1 + BEAM/ASCT No6y: 48
6y: 60
N.S.6y: 65
6y : 65
N.S.

Gisselbrecht [19] 2002181
189
Kiel/WHO 199962.5
60
B: 79
B: 75
97
99
CR, CRu, PR, SD, MR, PDACBVP3 versus CEOP3 + ECVBP + BEAM/ASCT Yes5y: 52
5y: 39
0.015y: 60
5y : 46
0.007

Kaiser [20] 2002154
158
REAL61
58
B: 79
B: 73
75
73
CR, CRu, PR, SD, MR, PDCHOEP1 × 5 versus CHOEP1 × 3 + BEAM/ASCT Yes3y: 49
3y: 59
N.S.3y: 63
3y: 62
N.S.

Martelli [21] 200375
75
REAL84
78
B: 81
B: 70
100
100
CR, CRu, PR, SD, MR, PDMACOP-B versus MACOP-B + BEAC/ASCT Yes5y: 49
5y: 61
N.S.5y: 65
5y: 64
N.S.

Olivieri [22]2005106
116
W.F.78
75
B: 83
B: 80
68
72
CR, CRu, PR, SD, MR, PDVACOP-B1 × 12 weeks versus VACOP-B1 × 8 weeks + HD-CTX + HD-VP16 + BEAM/ASCT No7y: 44.9
7y: 40.9
N.S.7y: 60
7y : 57
N.S.

Vitolo [23] 200566
60
REAL90
80
B: 96
B : 90
80
87
CR, CRu, PR, SD, MR, PDMega CEOP2 × 6–8 versus HDS# + mito-L-PAM2/ASCT No6y: 48
6y: 45
N.S.6y: 63
6y: 49
N.S.

Betticher [24] 200659
70
REAL69
76
B: 74
B: 93
88
72
CR, CRu, PR, SD, MR, PDCHOP2 × 8 versus HDS# + mito-L-PAM2/ASCT No3y: 33
3y: 39
N.S.3y: 53
3y: 46
N.S.

Lynch [25] 2010234
233
W.F. N.R. N.R.98
98
CR, CRu, PR, SD, MR, PDCHOP1 × 6–8 versus CHOP1 × 3 + BEAM/ASCT Yes5y: 38
5y: 44
N.S.5y: 50
5y: 50
N.S.

1Plus radiotherapy at bulky disease.
2Plus radiotherapy at bulky disease and intrathecal prophylaxis in very high-risk patients.
3Plus intrathecal prophylaxis in very high-risk patients.
#See [17, 23, 24].
W.F.: working formulation-NHL classification; Kiel: Kiel classification of NHL; WHO: World Health Organization classification of NHL; CR: complete response; CRu: unconfirmed complete response; PR: partial response; MR: minor response, SD: stable disease, PD: progressive disease; MACOP-B: methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin; HDS: high-dose sequential chemotherapy; mito-L-PAM: mitoxantrone and melphalan; VACOP-B: etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin; BEAM: carmustine, etoposide, cytarabine, and melphalan; ACBVP: doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone; (mega) CEOP: cyclophosphamide, epirubicin, vincristine, and prednisone; ECVBP: epirubicin, cyclophosphamide, vindesine, bleomycin, and prednisone; CHOEP: cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone; BEAC: carmustine, etoposide, cytarabine, and cyclophosphamide; HD-CTX: high-dose cyclophosphamide; HD-VP16: high-dose etoposide; N.R.: not reported; N.S.: not significant.